And you are so full of clues - upgrade to $30, mention in AF article - that's all in the past, this is OVER. In the near future - dilution in order to raise $$ for launch and no more upgrades.
I'll give you another clue - the ANALysts were tripping all over to upgrade in order for the institutions to dump their shares on you and to get a piece of underwriting fees from the coming capital raise.
And even if ISIS gets a CRL the stock won't go up because it would not affect the clue above.
And since you started this thread without quoting, I'll have to quote to fill in the void
Shorting another 5K shares of Aegerion $AEGR at $28.04 as they need $ and $ISIS is up for approval this month w/ a competing HOFH treatment.
Didn't think I'd get the opp. to short Aegerion $AEGR again so soon! $27.45 - Shorting it heavily now. $ISIS will take 50% of it's market.
Novapharm is an idiot. ISIS was denied by the EMEA and will probably be denied by the FDA too. Even if the FDA grants approval for ISIS, AEGR will have the drug of choice. Moreover, AEGR will receive EMEA approval and own the European market. AEGR is undervalued. The stock has a lot of momentum. ISIS is fumbling around. Just yesterday a few law firms are looking to sue the company. Wow. ISIS is crumbling and so is novapharm